Literature DB >> 16709871

CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function.

Benjamin D Medoff1, John C Wain, Edward Seung, Ryan Jackobek, Terry K Means, Leo C Ginns, Joshua M Farber, Andrew D Luster.   

Abstract

Lung transplantation remains the only effective therapy for patients with end-stage lung disease, but survival is limited by the development of obliterative bronchiolitis (OB). The chemokine receptor CXCR3 and two of its ligands, CXCL9 and CXCL10, have been identified as important mediators of OB. However, the relative contribution of CXCL9 and CXCL10 to the development of OB and the mechanism of regulation of these chemokines has not been well defined. In this study, we demonstrate that CXCL9 and CXCL10 are up-regulated in unique patterns following tracheal transplantation in mice. In these experiments, CXCL9 expression peaked 7 days posttransplant, while CXCL10 expression peaked at 1 day and then again 7 days posttransplant. Expression of CXCL10 was also up-regulated in a novel murine model of lung ischemia, and in bronchoalveolar lavage fluid taken from human lungs 24 h after lung transplantation. In further analysis, we found that 3 h after transplantation CXCL10 is donor tissue derived and not dependent on IFN-gamma or STAT1, while 24 h after transplantation CXCL10 is from recipient tissue and regulated by IFN-gamma and STAT1. Expression of both CXCL9 and CXCL10 7 days posttransplant is regulated by IFN-gamma and STAT1. Finally, we demonstrate that deletion of CXCR3 in recipients reduces airway obliteration. However, deletion of either CXCL9 or CXCL10 did not affect airway obliteration. These data show that in this murine model of obliterative bronchiolitis, these chemokines are differentially regulated following transplantation, and that deletion of either chemokine alone does not affect the development of airway obliteration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709871     DOI: 10.4049/jimmunol.176.11.7087

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Long-term exposure of chemokine CXCL10 causes bronchiolitis-like inflammation.

Authors:  Dianhua Jiang; Jiurong Liang; Rishu Guo; Ting Xie; Francine L Kelly; Tereza Martinu; Ting Yang; Alysia K Lovgren; Jessica Chia; Ningshan Liu; Yoosun Jung; Scott M Palmer; Paul W Noble
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-08       Impact factor: 6.914

Review 2.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 3.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

4.  Listr1 locus regulates innate immunity against Listeria monocytogenes infection in the mouse liver possibly through Cxcl11 polymorphism.

Authors:  Zanmei Qi; Jun Wang; Xue Han; Ji Yang; Guoming Zhao; Yaming Cao
Journal:  Immunogenetics       Date:  2014-02-25       Impact factor: 2.846

5.  Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.

Authors:  Eleanor Clancy-Thompson; Thomas J Perekslis; Walburga Croteau; Matthew P Alexander; Tamer B Chabanet; Mary Jo Turk; Yina H Huang; David W Mullins
Journal:  Cancer Immunol Res       Date:  2015-06-05       Impact factor: 11.151

6.  Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4.

Authors:  Dianhua Jiang; Jiurong Liang; Gabriele S Campanella; Rishu Guo; Shuang Yu; Ting Xie; Ningshan Liu; Yoosun Jung; Robert Homer; Eric B Meltzer; Yuejuan Li; Andrew M Tager; Paul F Goetinck; Andrew D Luster; Paul W Noble
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

7.  Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3.

Authors:  Tereza Martinu; Christine V Kinnier; Kymberly M Gowdy; Francine L Kelly; Laurie D Snyder; Dianhua Jiang; W Michael Foster; Stavros Garantziotis; John A Belperio; Paul W Noble; Scott M Palmer
Journal:  J Heart Lung Transplant       Date:  2011-03-27       Impact factor: 10.247

8.  CXCR3 in T cell function.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

9.  CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction.

Authors:  S S Weigt; A Derhovanessian; E Liao; S Hu; A L Gregson; B M Kubak; R Saggar; R Saggar; V Plachevskiy; M C Fishbein; J P Lynch; A Ardehali; D J Ross; H-J Wang; R M Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2011-12-07       Impact factor: 8.086

10.  Chemokine guidance of central memory T cells is critical for antiviral recall responses in lymph nodes.

Authors:  Jung Hwan Sung; Han Zhang; E Ashley Moseman; David Alvarez; Matteo Iannacone; Sarah E Henrickson; Juan C de la Torre; Joanna R Groom; Andrew D Luster; Ulrich H von Andrian
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.